+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Crohn's Disease (Regional Enteritis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • PDF Icon

    Report

  • 632 Pages
  • April 2022
  • Region: Global
  • Global Markets Direct
  • ID: 5589914
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The latest Pharmaceutical and Healthcare disease pipeline guide Crohn's Disease - Drugs In Development, 2022, provides an overview of the Crohn's Disease (Gastrointestinal) pipeline landscape.

Crohn’s disease is an inflammatory bowel disease (IBD). It causes inflammation of the lining of digestive tract, which can lead to abdominal pain, severe diarrhea and even malnutrition. Inflammation caused by Crohn’s disease can involve different areas of the digestive tract in different people. Signs and symptoms may include diarrhea, abdominal pain and cramping, blood in stool, ulcers, reduced appetite and weight loss. Risk factor include age, family history, smoking and use of Non-steroidal anti-inflammatory medications.

Report Highlights


The Pharmaceutical and Healthcare latest pipeline guide Crohn's Disease - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Crohn's Disease (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Crohn's Disease (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Crohn's Disease (Regional Enteritis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 13, 42, 37, 3, 77 and 37 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 1, 1, 1, 4 and 1 molecules, respectively.

Crohn's Disease (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Crohn's Disease (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Crohn's Disease (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Crohn's Disease (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Crohn's Disease (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Crohn's Disease (Gastrointestinal)

Reasons to Buy


  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Crohn's Disease (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Crohn's Disease (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

IntroductionReport CoverageCrohn's Disease (Regional Enteritis) - Overview
Crohn's Disease (Regional Enteritis) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
Crohn's Disease (Regional Enteritis) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Crohn's Disease (Regional Enteritis) - Companies Involved in Therapeutics DevelopmentCrohn's Disease (Regional Enteritis) - Drug ProfilesCrohn's Disease (Regional Enteritis) - Dormant ProjectsCrohn's Disease (Regional Enteritis) - Discontinued ProductsCrohn's Disease (Regional Enteritis) - Product Development Milestones
Featured News & Press Releases
  • Apr 19, 2022: People with moderate to severe uncontrolled Crohn’s disease granted early access to new investigational treatment in the UK
  • Apr 04, 2022: Thetis Pharmaceuticals secures $4.2 million from the Helmsley Charitable Trust to advance its first-in-class Resolvin oral therapy for Crohn’s Disease
  • Mar 30, 2022: Redx nominates GI-targeted ROCK inhibitor, RXC008, as clinical development candidate
  • Mar 28, 2022: Tiziana commences Phase Ib trial of Crohn’s disease antibody
  • Mar 24, 2022: Celltrion Healthcare wins tender to supply Remsimato the Brazilian Federal Government
  • Feb 28, 2022: AbbVie provides update regarding SKYRIZI (risankizumab-rzaa) for the treatment of moderate to severe Crohn's disease in the U.S.
  • Feb 24, 2022: Second phase 3 induction study confirms Upadacitinib (RINVOQ) improved clinical and endoscopic outcomes in patients with Crohn's disease
  • Feb 24, 2022: Second phase 3 induction study confirms Upadacitinib (RINVOQ) improved clinical and endoscopic outcomes in patients with Crohn's disease
  • Feb 20, 2022: Rapid improvement and remission in patients with refractory ulcerative colitis and crohn’s colitis after direct injection of Remestemcel-L by colonoscopy
  • Feb 18, 2022: The majority of adults with moderately to severely active Crohn’s disease in a phase 2 study achieved clinical remission and corticosteroid-free remission through 48 weeks with TREMFYA (guselkumab)
  • Feb 15, 2022: Statera Biopharma announces Central Institutional Review Board approval of phase 3 clinical trial for pediatric Crohn’s disease
  • Feb 04, 2022: Tiziana announces submission of amendment to Investigational New Drug Application to advance oral foralumab, a fully human anti-CD3 monoclonal antibody, in patients with crohn’s disease
  • Feb 04, 2022: Mitsubishi Tanabe’s 9 month sales rise fueled by strong growth in Stelara
  • Jan 06, 2022: Avalo reports positive phase 1b results for AVTX-002 in moderate to severe Crohn's disease patients and Presents Additional Program Updates at 2022 Investor Event
  • Dec 29, 2021: Statera Biopharma submits phase 3 clinical trial protocol to FDA for investigational treatment of pediatric Crohn’s Disease
AppendixMethodologyCoverageSecondary ResearchPrimary ResearchExpert Panel ValidationContact the Analyst
List of Tables
  • Number of Products under Development for Crohn's Disease (Regional Enteritis), 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products under Development by Universities/Institutes, 2022
  • Products under Development by Companies, 2022
  • Products under Development by Universities/Institutes, 2022
  • Number of Products by Stage and Target, 2022
  • Number of Products by Stage and Mechanism of Action, 2022
  • Number of Products by Stage and Route of Administration, 2022
  • Number of Products by Stage and Molecule Type, 2022
  • Crohn's Disease (Regional Enteritis) - Dormant Projects, 2022
  • Crohn's Disease (Regional Enteritis) - Discontinued Products, 2022

List of Figures
  • Number of Products under Development for Crohn's Disease (Regional Enteritis), 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products under Development by Universities/Institutes, 2022
  • Number of Products by Top 10 Targets, 2022
  • Number of Products by Stage and Top 10 Targets, 2022
  • Number of Products by Top 10 Mechanism of Actions, 2022
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2022
  • Number of Products by Top 10 Routes of Administration, 2022
  • Number of Products by Stage and Top 10 Routes of Administration, 2022
  • Number of Products by Top 10 Molecule Types, 2022
  • Number of Products by Stage and Top 10 Molecule Types, 2022

Companies Mentioned

A selection of companies mentioned in this report includes:

  • 4D Pharma Plc
  • 9 Meters Biopharma Inc
  • AbbVie Inc
  • Abivax SA
  • Aclaris Therapeutics Inc
  • Active Biotech AB
  • Affilogic SAS
  • AgomAb Therapeutics NV
  • AIBIOS Co Ltd
  • Alfasigma SpA
  • Algernon Pharmaceuticals Inc
  • Alpha Cancer Technologies Inc
  • Alvotech ehf
  • Amide Technologies Inc
  • Amytrx Therapeutics Inc
  • Anterogen Co Ltd
  • Artelo Biosciences Inc
  • Artizan Biosciences Inc
  • Asdera LLC
  • Asieris Pharmaceuticals Co Ltd
  • Assembly Biosciences Inc
  • AstraZeneca Plc
  • Atlantic Healthcare Plc
  • Avalo Therapeutics Inc
  • Avesthagen Ltd
  • Avexegen Therapeutics Inc
  • Avobis Bio LLC
  • Avotres Inc
  • Bio-Thera Solutions Ltd
  • Biocon Ltd
  • Biogen Inc
  • Biohaven Pharmaceutical Holding Company Ltd
  • BioXpress Therapeutics SA
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co
  • Cellivery Therapeutics Inc
  • CELLnLIFE Inc
  • Celltrion Inc
  • Cellvation Inc
  • Celularity Inc
  • ChemoCentryx Inc
  • Chong Kun Dang Pharmaceutical Corp
  • ChunLab Inc
  • Cloud Pharmaceuticals Inc
  • Curacle Co Ltd
  • CVasThera
  • Cytodyn Inc
  • Dadang & BIO Co Ltd
  • Daiichi Sankyo Co Ltd
  • Defensin Therapeutics ApS
  • Deka Biosciences Inc
  • Denali Therapeutics Inc
  • Direct Biologics LLC
  • DM Bio Ltd
  • DNX Biopharmaceuticals Inc
  • EA Pharma Co Ltd
  • Eden Biologics Inc
  • Educell doo
  • Eisai Co Ltd
  • Eli Lilly and Co
  • Enterome Bioscience SA
  • Enzo Biochem Inc
  • Exeliom Biosciences SAS
  • Ferring International Center SA
  • Finch Therapeutics Group Inc
  • First Wave BioPharma Inc
  • FYB 202 GmbH & Co KG
  • Galactica Biotech Ltd
  • Galapagos NV
  • Genentech USA Inc
  • Genor BioPharma Co Ltd
  • Giiant Pharma Inc
  • GlaxoSmithKline Plc
  • Gossamer Bio Inc
  • Gusto Global LLC
  • HAV Vaccines Ltd
  • Himuka AM Pharma Corp
  • Hoth Therapeutics Inc
  • Huaxia Source Cell Engineering Group Co Ltd
  • Iltoo Pharma
  • Immix BioPharma Inc
  • Immunic Inc
  • Immupharma Plc
  • InflammatoRx inc
  • Innovation Pharmaceuticals Inc
  • Innovative Pharmacology Research
  • Innovimmune Biotherapeutics Inc
  • Intract Pharma Ltd
  • Jiangsu Carephar Pharmaceutical Co Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • JiangSu Qyuns Therapeutics Co Ltd
  • Johnson & Johnson
  • Jyant Technologies Inc
  • Kangstem Biotech Co Ltd
  • Koutif Therapeutics LLC
  • Kyorin Pharmaceutical Co Ltd
  • Landos Biopharma Inc
  • Lumen Bioscience Inc
  • Machavert Pharmaceuticals LLC
  • MAKScientific LLC
  • Mesoblast Ltd
  • Metacrine Inc
  • Metagen Therapeutics Inc
  • MetiMedi Pharmaceuticals Co Ltd
  • MGC Pharmaceuticals Ltd
  • Mitsubishi Tanabe Pharma Corp
  • Morphic Therapeutic Inc
  • MRM Health NV
  • Mycenax Biotech Inc
  • NeuClone Pty Ltd
  • Novellus Therapeutics Ltd
  • Oncodesign SA
  • Orbsen Therapeutics Ltd
  • Orchard Therapeutics Plc
  • PanTheryx Inc
  • Par'Immune SAS
  • Paradigm Biopharmaceuticals Ltd
  • Parvus Therapeutics Inc
  • PeLeMed Co Ltd
  • Pfizer Inc
  • Pharmapraxis
  • Polpharma Biologics SA
  • Praeventix LLC
  • Prestige BioPharma Ltd
  • Prometheus Biosciences Inc
  • Puretech Health Plc
  • Qu Biologics Inc
  • Rebiotix Inc
  • Rebus Holdings Inc
  • RedHill Biopharma Ltd
  • Redx Pharma Plc
  • ReForm Biologics Inc
  • Regentys Corp
  • Reistone Biopharma Co Ltd
  • Reponex Pharmaceuticals AS
  • Saje Pharma LLC
  • Samsung Bioepis Co Ltd
  • Sangamo Therapeutics Inc
  • Saniona AB
  • Semorex Technologies Ltd
  • Servatus Ltd
  • Shenzhen Evergreen Therapeutics Co Ltd
  • Siam Bioscience Co Ltd
  • Soligenix Inc
  • Statera Biopharma Inc
  • Steel Therapeutics Inc
  • Stempeutics Research Pvt Ltd
  • STERO Biotechs Ltd
  • Sublimity Therapeutics HoldCo Ltd
  • Suono Bio Inc
  • Surrozen Inc
  • Suzhou Pharmavan Cancer Research Center Co Ltd
  • Synedgen Inc
  • Synlogic Inc
  • TaiwanJ Pharmaceuticals Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • Temisis Therapeutics
  • Tetherex Pharmaceuticals Corp
  • The Cell Factory BVBA
  • Theravance Biopharma Inc
  • Thetis Pharmaceuticals LLC
  • Tiziana Life Sciences Plc
  • TRACT Therapeutics Inc
  • Trio Medicines Ltd
  • UCB SA
  • Ventyx Biosciences Inc
  • VHsquared Ltd
  • VITAbolus Inc
  • Vitro Diagnostics Inc
  • Whan In Pharm Co Ltd
  • Winston Pharmaceuticals Inc
  • XBiotech Inc
  • Yom Chai
  • YSOPIA Bioscience SA